showed that in one case of NSCLC, a single nonsmoking patient who received afatinib before nivolumab developed grade 2 ILD after the administration of nivolumab, indicating that there is a possibility of ILD with an EGFR TKI administered before ICI therapy (37). This evidence concerns the gene EGFR and interstitial lung disease.